Hidradenitis Suppurativa

Hidradenitis suppurativa is a chronic inflammatory disease of the terminal hair follicle in apocrine-gland-rich skin — armpits, groin, buttocks, under the breasts — where follicles occlude, rupture and ignite deep dermal inflammation: painful nodules, abscesses, draining sinus tunnels and rope-like scars, recurring for decades. Prevalence estimates centre near 1% (likely undercounted), women outnumber men roughly three to one, onset clusters after puberty, smoking and obesity are the major modifiable associations (with genetics — a third report family history — and mechanical friction alongside), and the disease is neither an infection nor a hygiene failure: cultures of early lesions are typically sterile, and the scrubbing patients punish themselves with only inflames. The framing that changes everything downstream: HS is a systemic inflammatory disease with skin expression — carrying elevated cardiometabolic risk, inflammatory arthritis overlap, and quality-of-life scores among the worst measured in dermatology.

HS's defining system failure is delay: studies place average time from onset to diagnosis at seven to ten years — years of emergency-department lancings, repeated short antibiotic courses, and the label of recurrent boils, while tunnels and scars accumulate irreversibly. The recognition rule is simple enough to memorise: recurrent painful nodules or abscesses, in flexural apocrine sites, more than twice in six months — that triad is HS until proven otherwise, and warrants dermatology referral rather than another incision. Delay is not evenly distributed: it falls hardest where the disease does — on women, on Black patients (in whom prevalence runs higher in US data), and on the young — and every year of it forecloses the window in which medical therapy can prevent the structural damage surgery later has to remove.

Staged therapy now has real rungs. Mild disease: topical clindamycin, antiseptic washes, intralesional steroids for flares. Moderate: the tetracycline course, then the classic clindamycin-rifampicin combination; metformin and antiandrogens (spironolactone in women) as adjuncts with observational support. Moderate-to-severe: biologics — adalimumab (the first approval), secukinumab (2023), and bimekizumab (approved late 2024, with high inflammatory-response rates in its trial programme) — achieving meaningful response in roughly half of patients, transformative for many, insufficient for others. The pipeline just delivered its next wave: povorcitinib, an oral JAK1 inhibitor, met its phase 3 endpoints (STOP-HS: ~40-42% HiSCR50 at week 12 versus ~29% placebo, rising through week 54 in extension data) with US submission in 2026 — poised to become the first approved oral targeted therapy — and sonelokimab, an IL-17A/F Nanobody, delivered positive phase 3 results (VELA, the first programme judged on the stricter HiSCR75) with sustained 40-week responses; both presented landmark data in 2026. For a disease that had one biologic a few years ago, the shelf is finally crowding.

Medical therapy calms inflammation; it does not dismantle tunnels or excise tract-riddled tissue — which is why surgery remains co-equal, not a defeat. The proportionate menu: deroofing (unroofing tunnels under local anaesthesia — tissue-sparing, low-recurrence for fixed tracts), punch debridement of recurrent nodules, laser therapies, and wide local excision with reconstruction for end-stage regional disease — increasingly performed on biologic cover, with combined medical-surgical care the explicit modern standard. What deserves retirement: the lance-and-release cycle of emergency incision and drainage, which relieves the abscess and guarantees the recurrence, teaching patients that nothing works. Adjacent essentials: pain management taken seriously (HS pain is routinely undertreated), wound-care support for draining disease, friction and dressing strategies, and smoking cessation plus weight management framed as disease modification with observational support — never as blame.

HS's measured quality-of-life impact exceeds psoriasis and rivals the worst of chronic disease: pain chronically undertreated, drainage and odour managing daily logistics, intimacy and relationships strained (lesion sites are intimate sites), work impaired by flares and dressings, and depression rates among dermatology's highest — with the disease's demographic (young women, disproportionately of colour, often heavier) intersecting every documented pattern of medical dismissal. Comorbidity care belongs in the plan: metabolic screening (the syndrome travels with HS), inflammatory arthropathy asked about, and mental health screened proactively rather than noted in passing. Patient organisations and specialised HS clinics — multiplying since the biologic era gave the disease a market and a research base — supply the navigation, validation and trial access the seven lost years denied; connecting patients to them is treatment.

If you get recurrent painful lumps in the armpits, groin or under the breasts: that pattern has a name, a specialty and a treatment ladder — ask directly about hidradenitis suppurativa and request dermatology referral; do not accept indefinite lance-and-antibiotic cycles. Already diagnosed: know the ladder (topicals → tetracyclines → clindamycin-rifampicin → biologics, with adalimumab, secukinumab and bimekizumab approved and oral JAK therapy arriving), know that fixed tunnels are surgical and deroofing is far smaller than it sounds, and insist pain and mood are on the agenda. Smoking cessation and weight loss are the two self-directed disease modifiers with evidence — pursued as levers, never accepted as blame. And if current therapy is failing: HS is now one of dermatology's hottest trial fields — a specialised HS clinic can put the pipeline to work for you.